Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject has a diagnosis of RA as defined by the 1987 revised American College of Rheumatology (ACR) classification criteria and/or the ACR/the European League against Rheumatism (EULAR) 2010 classification criteria (any duration since diagnosis).
Male or female subjects \>= 18 years of age (local definition according to adalimumab label) who is in compliance with eligibility for adalimumab based on the local label.
Patients with moderate to severe RA defined as Disease Activity Score in 28 Joints (DAS28) Erythrocyte Sedimentation Rate (ESR) or DAS28 C- Reactive Protein (CRP) \>3.2
Biologically treatment naïve and initiated adalimumab at baseline visit
Availability of clinical data of the previous 12 weeks prior to baseline
Ability to self-complete patient questionnaires
Subject must be able and willing to provide written informed consent and comply with the requirements of this study protocol.
You may not be if
Patients who are pregnant or breast feeding at enrolment or wish to become pregnant in the next 24 weeks.
Participation in any RA-related clinical trial at the time of enrolment, at baseline or at any point during the past 24 weeks prior to baseline
Patients, who in the clinician's view, may not be able to accurately report their QoL or prior resource utilization
Patients, who in the clinician's view, may not be able to adhere to adalimumab therapy over 24 weeks.
Clareo Health | Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan
